scholarly journals Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphoma

2016 ◽  
Vol 50 (4) ◽  
pp. 360-369 ◽  
Author(s):  
Kursat Okuyucu ◽  
Sukru Ozaydın ◽  
Engin Alagoz ◽  
Gokhan Ozgur ◽  
Semra Ince ◽  
...  
Keyword(s):  
Overall Survival ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Disease Free Survival ◽  
Extranodal Lymphoma ◽  
Free Survival ◽  
Primary Staging ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Disease Free

Abstract Background Non-Hodgkin’s lymphomas arising from the tissues other than primary lymphatic organs are named primary extranodal lymphoma. Most of the studies evaluated metabolic tumor parameters in different organs and histopathologic variants of this disease generally for treatment response. We aimed to evaluate the prognostic value of metabolic tumor parameters derived from initial FDG-PET/CT in patients with a medley of primary extranodal lymphoma in this study. Patients and methods There were 67 patients with primary extranodal lymphoma for whom FDG-PET/CT was requested for primary staging. Quantitative PET/CT parameters: maximum standardized uptake value (SUVmax), average standardized uptake value (SUVmean), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were used to estimate disease-free survival and overall survival. Results SUVmean, MTV and TLG were found statistically significant after multivariate analysis. SUVmean remained significant after ROC curve analysis. Sensitivity and specificity were calculated as 88% and 64%, respectively, when the cut-off value of SUVmean was chosen as 5.15. After the investigation of primary presentation sites and histo-pathological variants according to recurrence, there is no difference amongst the variants. Primary site of extranodal lymphomas however, is statistically important (p = 0.014). Testis and central nervous system lymphomas have higher recurrence rate (62.5%, 73%, respectively). Conclusions High SUVmean, MTV and TLG values obtained from primary staging FDG-PET/CT are potential risk factors for both disease-free survival and overall survival in primary extranodal lymphoma. SUVmean is the most significant one amongst them for estimating recurrence/metastasis.

Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer

2014 ◽  
Vol 56 (12) ◽  
pp. 1463-1470 ◽  
Author(s):  
Ji Eun Jo ◽  
Jin You Kim ◽  
Suck Hong Lee ◽  
Suk Kim ◽  
Taewoo Kang
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Disease Free Survival ◽  
Free Survival ◽  
Invasive Ductal Breast Cancer ◽  
Ductal Breast Cancer ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Disease Free

scholarly journals 18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer.

2019 ◽  
Author(s):  
Styliani Mantziari ◽  
Anastasia Pomoni ◽  
John O Prior ◽  
Michael Winiker ◽  
Pierre Allemann ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Fdg Pet ◽  
Tumor Recurrence ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Free Survival ◽  
Pet Ct ◽  
Early Tumor ◽  
Fdg Pet Ct ◽  
Disease Free

Abstract Background Although 18 F- FDG PET/CT is validated in baseline workup of esophageal cancer to detect distant metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to evaluate the association between 18 F- FDG PET/CT-derived parameters of esophageal cancer, and its clinico-pathological features and prognosis.Methods All patients (n=86) with esophageal adenocarcinoma or squamous cell cancer operated between 2005-2014 were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the tumor’s maximal Standardized Uptake Value (SUV max ), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3/4) status, long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses.Results High baseline SUV max was associated with cT3/4 status and middle-third tumor location, TLG with a cT3/4 and cN+ status, whereas MTV only with active smoking. A cT3/4 status was significantly predicted by a SUV max >8.25g/mL (p<0.001), TLG>41.7 (p<0.001) and MTV>10.70 cm 3 (p<0.01) whereas a SUV max > 12.7 g/mL was associated with an early tumor recurrence and a poor disease-free survival (median 13 versus 56 months, p=0.030), particularly in squamous cell cancer.Conclusions Baseline 18 F- FDG PET/CT has a high predictive value of preoperative cT stage, as its parameters SUV max , TLG and MTV can predict a locally advanced tumor with high accuracy. A SUV max > 12.7 g/mL may herald early tumor recurrence and poor disease-free survival.

scholarly journals CLINICAL IMPACT OF 18F FDG PET-CT ON MANAGEMENT OF GERM CELL TUMORS

2015 ◽  
Vol 1 (2) ◽  
Author(s):  
Saima Riaz ◽  
Humayun Bashir ◽  
Nargis Muzzafar ◽  
Ahmed Murtaza ◽  
Amin Hayee
Keyword(s):  
Germ Cell ◽  
Fdg Pet ◽  
Disease Free Survival ◽  
Emission Tomography ◽  
Ct Scans ◽  
Free Survival ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Disease Free

Purpose: The purpose of this study was to review the impact of 18F- fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) scans on the management of patients with germ cell tumours (GCT) at our centre. Methods: A descriptive, cross-sectional, retrospective review of a total of 29 FDG PET-CT scans acquired in 20 patients with GCT between December 2009 and May 2013. Results: Sixteen males and four females with the average age of 34.4 years (+18SD) were identi ed who underwent FDG PET-CT scans for treatment response/outcome evaluation on an average period of 3 months after completion of therapy. Hypermetabolic residual disease (PET-CT positive) was identi ed in 8 (40%). 6 (30%) had non-FDG-avid residual morphologic disease (PET negative and CT positive) and 6 (30%) were disease free (PET-CT negative). FDG PET-CT led to change in the management plan of 12 (60%) of cases as compared to the CT alone ndings. Follow-up was available for a median of 2.9 years (±1.5 SD). The overall 5-year disease-free survival was found to be PET-CT positive patients = 62%, PET-negative and CT-positive patients = 80% and PET-CT-negative patients = 100%. Conclusion: FDG PET-CT scanning has a potential role in the evaluation of response to treatment and can predict the survival outcome. Key words: 18F- uorodeoxyglucose positron emission tomography computed tomography, disease-free survival, germ cell tumour, standardised uptake value 

scholarly journals 18 F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer.

2019 ◽  
Author(s):  
Styliani Mantziari ◽  
Anastasia Pomoni ◽  
John O Prior ◽  
Michael Winiker ◽  
Pierre Allemann ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Fdg Pet ◽  
Tumor Recurrence ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Free Survival ◽  
Pet Ct ◽  
Early Tumor ◽  
Fdg Pet Ct ◽  
Disease Free

Abstract Background Although 18 F- FDG PET/CT is validated in baseline workup of esophageal cancer to detect distant metastases, it remains underused in assessing local staging and biology of the primary tumor. This study aimed to evaluate the association between 18 F- FDG PET/CT-derived parameters of esophageal cancer, and its clinico-pathological features and prognosis.Methods All patients (n=86) with esophageal adenocarcinoma or squamous cell cancer operated between 2005-2014 were analyzed. Linear regression was used to identify clinico-pathologic features of esophageal cancer associated with the tumor’s maximal Standardized Uptake Value (SUV max ), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). ROC curve analysis was performed to precise the optimal cutoff of each variable associated with a locally advanced (cT3/4) status, long-term survival and recurrence. Kaplan Meier curves and Cox regression were used for survival analyses.Results High baseline SUV max was associated with cT3/4 status and middle-third tumor location, TLG with a cT3/4 and cN+ status, whereas MTV only with active smoking. A cT3/4 status was significantly predicted by a SUV max >8.25g/mL (p<0.001), TLG>41.7 (p<0.001) and MTV>10.70 cm 3 (p<0.01) whereas a SUV max > 12.7 g/mL was associated with an early tumor recurrence and a poor disease-free survival (median 13 versus 56 months, p=0.030), particularly in squamous cell cancer.Conclusions Baseline 18 F- FDG PET/CT has a high predictive value of preoperative cT stage, as its parameters SUV max , TLG and MTV can predict a locally advanced tumor with high accuracy. A SUV max > 12.7 g/mL may herald early tumor recurrence and poor disease-free survival.

Role of 18F-PET-CT to Predict Pathological Response After Neoadjuvant Treatment of Rectal Cancer

2021 ◽  
Author(s):  
Riccardo Caruso ◽  
Emilio Vicente ◽  
Yolanda Quijano ◽  
Hipolito Duran ◽  
Isabel Fabra ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Fdg Pet ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Standardized Uptake Value ◽  
Disease Free Survival ◽  
Pet Ct ◽  
Significant Difference ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Objectives: Neoadjuvant radiochemotherapy (nCRT) is universally considered to be a valid treatment to achieve downstaging, improve local disease control and obtain better resectability in locally advanced rectal cancer (LARC). The aim of this study is to correlate the change in tumor 18F -FDG PET-CT standardized uptake value (SUV) before and after nCRT, in order to obtain an early prediction of pathologic response (pR) achieved in patients with LARC.Data description: We performed a retrospective analysis of patients with LARC diagnosis who underwent curative resection. All patients received nCRT and surgical treatment was carried after 8/12th. All patients underwent a baseline 18F -FDG PET-CT scan within the week prior to the initiation of the treatment (PET-CT SUV1) and a second scan (PET-C T SUV2) within six weeks of the completion of nCRT. Furthermore, we evaluated the prognostic value of 18F -FDG PET-CT in terms of disease free survival (DFS) and overall survival (OS) in patients with LARC.A total of 133 patients with LARC were included in the study. Patients were divided in two groups according to the TRG (tumor regression grade): 107 (80%) as Responders group (TRG0-TRG1) and 26 (25%) as the No-Responders group (TRG2-TRG3). We obtained a significant difference in Δ%SUV between the two different groups responders vs no responders (p<0.012).The results of this analysis have shown that 18F-FDG PET-CT may be an indicator in order to evaluate the pR to nCRT in patients with LARC. The decrease in 18F-FDG PET-CT uptake in the primary tumor may offer primary information in order to early identify those patients more likely to obtain a pCR to nCRT and predict those unlikely to regress significantly.

Overall and disease-free survival outcomes of patients receiving intensity-modulated radiation therapy (IMRT) with PET-CT-based planning for cancers of the head and neck

2015 ◽  
pp. 1-11
Author(s):  
Benjamin L. Franc ◽  
Christi DeLemos ◽  
Christopher Jones
Keyword(s):  
Overall Survival ◽  
Metastatic Disease ◽  
Intensity Modulated Radiation Therapy ◽  
Disease Free Survival ◽  
Survival Outcomes ◽  
Free Survival ◽  
Distant Metastatic Disease ◽  
Intensity Modulated ◽  
Pet Ct ◽  
Disease Free

AbstractIntroductionCombined modality treatment regimens have provided modest gains in locoregional control rates of cancers of the head and neck (HNC), and intensity-modulated radiation therapy (IMRT) has gained widespread use. The methodology for determining contours of the gross tumour volume (GTV) in the radiation treatment plan is often based on combined anatomic and metabolic data from positron emission tomography–computed tomography (PET-CT). This study aimed to retrospectively evaluate the overall survival and disease-free survival outcomes of patients with HNC who received definitive IMRT with or without chemotherapy, planned with PET-CT.Materials and MethodsA total of 1,200 patients underwent treatment for HNC during the study period, from 1 January 2002 to 31 December 2010. Of those, 261 cases had evaluable data that met the inclusion criteria for the study. The incidence and timing of locoregional recurrence, distant metastatic disease, new primary malignancies and death were evaluated retrospectively. Overall and disease-free survival (survival to time of first recurrence) were determined by the life table method. Incidence of distance metastatic disease and additional cancers were also studied.ResultsMedian follow-up from treatment initiation was 26·4 months (range 1·2–84·7 months). Overall survival and disease-free survival rates were 0·883 and 0·791, respectively, at 1 year; 0·793 and 0·688, respectively, at 2 years; and 0·732 and 0·619, respectively, at 3 years. The cumulative risk of recurrence was 22·6% at 3 years following definitive IMRT and the median time to recurrence was 345 days. There was an overall low incidence of distant metastatic disease (3·07%) and additional cancers (8·05%).ConclusionOverall and disease-free survival outcomes of a large cohort of HNC patients treated with definitive IMRT radiotherapy following treatment planning with PET-CT shows a similar high level of disease control and mortality rate as previously published outcome studies of shorter terms and/or smaller numbers of patients.

Value of FDG-PET/CT findings revised using an anthropomorphic body phantom for the evaluation of tumor malignancy grade in small-sized lung adenocarcinomas: A multicenter study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 7573-7573
Author(s):  
H. Nakayama ◽  
Y. Kato ◽  
M. Tsuboi ◽  
S. Okumura ◽  
H. Daisaki ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Disease Free Survival ◽  
Ground Glass Opacity ◽  
Bronchioloalveolar Carcinoma ◽  
Malignancy Grade ◽  
Pathologic Features ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Malignant Behavior

7573 Background: The malignant behavior of small lung adenocarinomas (AD), which have been detected with increasing frequency recently, has not yet been clearly evaluated, and an understanding of this biological characteristic is vital for selecting the appropriate therapeutic strategy. We examined the malignancy grade of small lung ADs using FDG-PET/CT (PET), in addition to high-resolution CT (HRCT) and pathologic evaluation in a multicenter setting. Methods: A total of 204 patients with cT1N0M0 AD underwent PET and HRCT, followed by complete resection with lymph node dissection. The associations between components of bronchioloalveolar carcinoma (BAC) on pathologic examination and maximum standardized uptake value (maxSUV) on PET, ground-glass opacity (GGO) ratio and tumor disappearance rate (TDR) on HRCT were examined, and these findings were analyzed in relation to pathologic features and surgical outcomes. To reduce the errors in PET machines used for this analysis, maxSUV data were adjusted using an anthropomorphic body phantom of the NEMA standards (corrected maxSUV). Results: Examination of tumor aggressiveness based on the presence of lymphatic, vascular and pleural invasion, and of nodal metastasis, showed that maxSUV, BAC ratio, TDR, and GGO ratio, in the order, can reflect the malignancy grade. MaxSUV and BAC ratio were also valuable prognostic predictors of the disease-free survival. There were no significant differences in the values between maxSUV and corrected maxSUV. Although BAC ratio was significantly associated with maxSUV, GGO ratio and TDR (all p<0.0001), the degree of association with maxSUV (R2=0.2533) was weaker than that with GGO (R2=0.5843) ratio or TDR (R2=0.5123). Conclusions: A higher maxSUV reflects an aggressive malignant behavior of cT1N0M0 ADs, independently of BAC component. Assessment by PET in addition to HRCT is useful for selection of the appropriate treatment strategy for small lung AD. [Table: see text] No significant financial relationships to disclose.

scholarly journals The Preoperative Maximum Standardized Uptake Value Measured by 18F-FDG PET/CT as an Independent Prognostic Factor of Overall Survival in Endometrial Cancer Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Malgorzata Walentowicz-Sadlecka ◽  
Bogdan Malkowski ◽  
Pawel Walentowicz ◽  
Pawel Sadlecki ◽  
Andrzej Marszalek ◽  
...  
Keyword(s):  
Overall Survival ◽  
Endometrial Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Maximum Standardized Uptake Value ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Purpose. The aim of this study was to determine if the preoperative maximum standardized uptake value (SUVmax) measured by 18F-FDG PET/CT in the primary tumor has prognostic value in the group of patients with endometrial cancer.Patients, Materials, and Methods. A total of one hundred one consecutive endometrial cancer patients, age range 40–82 years (mean 62 years) and FIGO I–IV stage, who underwent 18-FDG-PET/CT within two weeks prior radical surgery, were enrolled to the study. The maximum SUV was measured and compared with the clinicopathologic features of surgical specimens. The relationship between SUVmax and overall survival was analyzed.Results. The mean preoperative SUVmax was 14.34; range (3.90–33.80) and was significantly lower for FIGO I than for higher stages (P=0.0012), as well as for grade 1 than for grade 2 and 3 (P=0.018), deep myometrial invasion (P=0.0016) and for high risk group (P=0.0004). The analysis of survival ROC curve revealed SUVmax cut-off value of 17.7 to predict high risk of recurrence. Endometrial cancer patients with SUVmax higher than 17.7 characterized by lower overall survival.Conclusion. The preoperative SUVmax measured by 18F-FDG PET/CT is considered as an important indicator reflecting tumor aggressiveness which may predict poor prognosis. High value of SUVmax would be useful for making noninvasive diagnoses and deciding the appropriate therapeutic strategy for patients with endometrial cancer.

The prognostic value of FDG-PET measured by standardized uptake value in patients with melanoma stage III evaluated in a prospective study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20000-e20000
Author(s):  
E. Bastiaannet ◽  
J. R. De Jong ◽  
A. H. Brouwers ◽  
A. J. Suurmeijer ◽  
H. J. Hoekstra
Keyword(s):  
Lymph Node ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Standardized Uptake Value ◽  
Disease Free Survival ◽  
Free Survival ◽  
Node Metastasis ◽  
Node Metastases ◽  
Melanoma Patients ◽  
Disease Free

e20000 Background: FDG-PET is a sensitive modality to detect melanoma metastases; melanomas are typically FDG-avid and melanoma shows an unpredictable pattern of spread. Furthermore, FDG-PET is able to quantify FDG uptake and the amount of FDG uptake, measured by the standardized uptake value (SUV), might be important for the prediction of disease specific survival (DSS) or disease free survival (DFS). Therefore, aim of this study was to perform a prospective analysis to determine whether SUV is of prognostic value in the DFS and DSS of melanoma patients with palpable lymph node metastases. Methods: From July 2002 until December 2007, all consecutive patients with palpable, histology or cytology proven lymph node metastases of melanoma referred to the University Medical Centre Groningen for examination with FDG-PET were prospectively included. The SUVmean (70% isocontour) and SUVmax in the lymph node metastasis were calculated for patients who showed no distant metastases on chest X-Ray, FDG-PET and CT. Univariate and multivariate survival analysis was performed to determine whether SUV was associated with DFS and DSS (Cox Proportional Hazard analysis). Results: Overall, 70 patients were eligible. High SUV values were present in axillary metastases (p=0.118), in patients who had more than 15 nodes removed (p=0.061) and in patients with a large tumor size in the lymph node (p=0.0001). Patients with a low SUVmean had a 3-years DFS of 54.3% as compared to 28.1% for patients with a high SUVmean (HR 2.02;p=0.051). In multivariate analysis SUVmean seems to be associated with DFS (p=0.063). DSS for patients with a high SUV was decreased, however not statistically significant (HR 1.71; p=0.182). Conclusions: The SUV in the lymph node metastasis seems to be associated with disease-free survival for melanoma patients clinically stage III. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document